Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five join MHRA's BP Commission

This article was originally published in Scrip

Executive Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA)'s British Pharmacopoeia Commission, which is responsible for preparing new editions of the BP and the BP (Veterinary), has appointed five new members: Andrew Coulson, a member of the Royal College of Veterinary Surgeons; Dr Gerard Lee, who worked at the MHRA from 1999 to December 2011, most recently as group manager of the British Pharmacopoeia and Laboratory Services section; Dr Ronald Torano, a GlaxoSmithKline employee since 1989 and currently pharmacopoeial intelligence and advisory specialist; Dr Paul Varley, vice-president of biopharmaceutical development at Medimmune; and Professor John Miller, visiting professor to the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde, and former head of laboratory department for the Council of Europe's EDQM.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel